Ironwood Pharmaceuticals, Inc. (FRA:I76)

Market Cap	669.57M +15.1%
Revenue (ttm)	288.92M -10.4%
Net Income	24.33M
EPS	0.15
Shares Out	n/a
PE Ratio	27.52
Forward PE	6.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	345
Open	3.900
Previous Close	4.040
Day's Range	3.880 - 3.900
52-Week Range	0.478 - 4.480
Beta	n/a
RSI	54.65
Earnings Date	Feb 17, 2026

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 253
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I76

Financial Performance

Financial numbers in USD